Objective: remission of depression in primary care The Oreon Study.

Antidepressive Agents/therapeutic use; Depression/drug therapy/epidemiology/psychology; Disability Evaluation; Female; Humans; Logistic Models; Male; Middle Aged; Physicians, Family/psychology; Primary Health Care/statistics & numerical data; Psychiatric Status Rating Scales; Quality of Life/psychology; Remission, Spontaneous; Social Environment; Treatment Outcome

Abstract :

[en] OBJECTIVE: Treatment of depression should result in the absence of symptoms, i.e. remission, in order to restore the functional status of the patient and reduce the risk for relapse. The study assessed the current remission rates in primary care and determined the influencing factors. METHODS: 10 consecutive depressive patients treated by antidepressants for at least 3 months and not more than 12 months were screened by each investigator. Remission rates were defined using the Hamilton-Depression scale 7 items (score of 3 or less) as well as the Carroll self rating scale (score of 7 or less). In addition, patients completed the Sheehan Disability Scale (SDS). Initial severity of depression, type of treatment and socio-economic factors were collected. RESULTS: 292 general practitioners screened a total of 2630 patients. Results indicated low remission rates: 28.3% according to the clinician and 17.1% according to the patient. Absence of remission was associated with higher impairment in work, social and family life. The most frequently reported residual symptoms in nonremitters were general somatic symptoms (92%), depressed mood (92%), psychic anxiety (91%) and impaired work and activities (89%). No differences were observed in remission rates between men and women. Remission rates were significantly lower in patients living alone as compared to those living in couple or family (25.1% vs 30.2%, p=0.03), in patients with lower education (21.3% vs 32.3%, p<0.001), in patients speaking French as compared to Dutch (24.0% vs 34.0% p<0.001), and unemployed patients compared to patients having an occupation (17.1% vs 39.0%, p<0.001). Higher initial severity and number of previous episodes decreased remission rates (p<0.001). CONCLUSION: This study shows low remission rates in depressed patients treated in general practice. The absence of remission is associated with impairment in work, social and family life. Special attention should be given to identify patients who do not reach remission.

Disciplines :

Psychiatry

Author, co-author :

Ansseau, Marc ; Université de Liège - ULiège > Département des sciences cliniques > Psychiatrie et psychologie médicale

Demyttenaere, Koen

Heyrman, Jan

Migeotte, André ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale

Leyman, Sophie

Mignon, Annick

Language :

English

Title :

Objective: remission of depression in primary care The Oreon Study.

Publication date :

2009

Journal title :

European Neuropsychopharmacology

ISSN :

0924-977X

eISSN :

1873-7862

Publisher :

Elsevier Science, Amsterdam, Netherlands

Volume :

Issue :

Pages :

169-76

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 25 August 2011

Statistics

Number of views

58 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am. J. Psychiatry 157 (2000) 1-45
Anderson I.M., Nutt D.J., and Deakin J.F. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J. Psychopharmacol. 14 (2000) 3-20
Ansseau M., Dierick M., Buntinkx F., Cnockaert P., De Smedt J., Van Den Haute M., and Vander Mijnsbrugge D. High prevalence of mental disorders in primary care. J. Affect. Disord. 78 (2004) 49-55
Ansseau M., Fischler B., Dierick M., Mignon A., and Leyman S. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: The GADIS study. Eur. Psychiatr. 20 (2005) 229-235
Bauer M., Whybrow P.C., Angst J., Versiani M., and Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBF) Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthrehold depressions. World J. Biol. Psychiatry 3 (2002) 69-86
Belgian Government Federal Statistics 2005.
Canadian Psychiatric Association; Canadian Network of Mood and Anxiety Treatments (CANMAT). Clinical guidelines for the treatment of depressive disorders. Can. J. Psychiatry 46 Suppl 1 (2001) 5S-90S
Carroll B.J., Feinberg M., Smouse P.E., Rawson S.G., and Greden J.F. The Carroll rating scale for depression. I. Development, reliability and validation. Br. J. Psychiatry 138 (1981) 194-200
Charles G., Frydman O., Bonami T., Hershkowitz C., Tilmant J.J., Wilmotte J., and Mendlewicz J. French adaptation and validation of the Carroll rating scale for depression. Encephale 12 (1986) 299-301
Corruble E., Legrand J.M., Zvenigorowski H., Duret C., and Guelfi J.D. Concordance between self-report and clinician's assessment of depression. J. Psychiatr. Res. 33 (1999) 457-465
De Graaf R., Bijl R.V., Ravelli A., Smit F., and Vollebergh W.A. Predictors of first incidence of DSM-III-R psychiatric disorders in the general population: findings from the Netherlands Mental Health Survey and Incidence study. Acta Psychiatr. Scand. 106 (2002) 303-313
Domken M., Scott J., and Kelly P. What factors predict discrepancies between self and observer ratings of depression?. J. Affect. Disord. 31 (1994) 253-259
Ellis P. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust. N. Z. J. Psychiatry 38 (2004) 389-407
Enns M.W., Larsen D.K., and Cox J.B. Discrepancies between self and observer ratings of depression. The relationship to demographic, clinical and personality variables. J. Affect. Disord. 60 (2000) 33-41
Feinberg M., Carroll B.J., Smouse P.E., and Rawson S.G. The Carroll rating scale for depression. III. Comparison with other rating instruments. Br. J. Psychiatry 138 (1981) 205-209
Frank E., Prien B.B., Jarrett R.B., et al. Conceptualization and nationale for consensus definitions of terms in major depressive disorder. Arch. Gen. Psychiatry 48 (1991) 851-855
Gilbody S., Whitty P., Grimshaw J., and Thomas R. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA 289 (2003) 3145-3151
Hirschfeld R.M., Montgomery S.A., Aguglia E., Amore M., Delgado P.L., Gastpar M., Hawley C., Kasper S., Linden M., Massana J., Mendlewicz J., Moller H.J., Nemeroff C.B., Saiz J., Such P., Torta R., and Versiani M. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J. Clin. Psychiatry 63 (2002) 826-837
Gruen R.L., Weeramanthri T.S., Knight S.E., and Bailie R.S. Specialist outreach clinics in primary care and rural hospital settings. Cochrane Database Syst. Rev. 1 (2004) CD003798
Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
Hirschfeld R.M., Russel J.M., Delgado P.L., Fawcett J., Friedman R.A., Harrison W.M., Koran L.M., Miller I.W., Thase M.E., Howland R.H., Connolly M.A., and Miceli R.J. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J. Clin. Psychiatry 59 12 (1998) 669-675
Joyce P.R., and Paykel E.S. Predictors of drug response in depression. Arch. Gen. Psychiatry 46 (1989) 89-99
Judd L.L., Paulus M.J., Schettler P.J., Akiskal H.S., Endicott J., Leon A.C., Maser J.D., Mueller T., Solomon D.A., and Keller M.B. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?. Am. J. Psychiatry 157 (2000) 1501-1504
Keller M.B. Past, present, and future directions for defining optimal treatment outcome in depression. JAMA 289 (2003) 3152-3160
Leon A.C., Olfson M., Portera L., Farber L., and Sheehan D.V. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int. J. Psychiatry Med. 27 (1997) 93-105
McIntyre R., Kennedy S., Bagby R.M., and Bakish D. Assessing full remission. J. Psychiatry Neurosci. 27 (2002) 235-239
McIntyre R., Konarski J.Z., Mancini D.A., Fulton K.A., Parikh S.V., Grigoriadis S., Grupp L.A., Bakish D., Filteau M.J., Gorman C., Nemeroff C.B., and Kennedy S.H. Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. CMAJ 173 (2005) 1-8
Miller I.W., Keitner G.I., Schatzberg A.F., Klein D.N., Thase M.E., Rush A.J., Markowitz J.C., Schlager D.S., Kornstein S.G., Davis S.M., Harrison W.M., and Keller M.B. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J. Clin. Psychiatry 59 (1998) 608-619
Murphy J.M., Monson R.R., Olivier D.C., Sobol A.M., and Leighton A.H. Affective disorders and mortality. A general population study. Arch. Gen. Psychiatry 44 (1987) 473-480
Nasr S.J., Altman E.G., Rodin M.B., Jobe T.H., and Burg B. Correlation of the Hamilton and Carroll depression rating scales. A replication study among psychiatric outpatients. J. Clin. Psychiatry 45 (1984) 167-168
Nierenberg A.A., Keefe B.R., Leslie V.C., Alpert J.E., Pava J.A., Worthington J.J., Rosenbaum J.F., and Fava M. Residual symptoms in depressed patients who respond acutely to fluoxetine. J. Clin. Psychiatry 60 (1999) 221-225
Nierenberg A.A., and Wright E.C. Evolution of remission as the new standard in the treatment of depression. J. Clin. Psychiatry 60 suppl 22 (1999) 7-11
Nierenberg A., Sussman N., and Trivedi M. Managing relapse in depression (2003), Science Press, London
Ohayon M.M., and Lader M.H. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J. Clin. Psychiatry 63 (2002) 817-825
Pelissolo A., Boyer P., Lepine J.P., and Bisserbe J.C. Epidémiologie de la consommation des anxiolytiques et des hypnotiques en France et dans le monde. Encéphale 22 (1996) 187-196
Pintor L., Gasto C., Navarro V., Torres X., and Fananas L. Relapse of major depression after complete and partial remission during a 2-year follow-up. J. Affect. Disord. 73 (2003) 237-244
Pintor L., Torres X., Navarro V., Matrai S., and Gasto C. Is the type of remission after a major depressive episode an important risk factor to relapses in a 4-year follow up?. J. Affect. Disord. 82 (2004) 291-296
Rush A.J., Hiser W., and Giles D.E. A comparison of self-reported versus clinician-related symptoms in depression. J. Clin. Pscyhiatry 48 (1987) 246-248
Sheehan D.V. The Anxiety Disease (1983), Scribner's, New York
Simon G.E. Long-term prognosis of depression in primary care. Bull. World Health Organ. 78 (2000) 439-445
Smouse P.E., Feinberg M., Carroll B.J., Park M.H., and Rawson S.G. The Carroll rating scale for depression. II. Factor analyses of the feature profiles. Br. J. Psychiatry 138 (1981) 201-204
Spitzer R.L., Williams J.B.W., Kroenke K., Linzer M., Verloin deGruy III F., Hahn S.R., Brody D., and Johnson J.G. Utility of a new procedure for diagnosing mental disorders in primary care. JAMA 272 (1994) 1749-1756
Swindle Jr. R.W., Cronkite R.C., and Moos R.H. Risk factors for sustained nonremission of depressive symptoms: a 4-year follow-up. J. Of Nerv. Ment. Dis. 186 (1998) 462-469
Szadoczky E., Rozsa S., Zambon J., and Füredi J. Predictors for 2-year outcome of major depressive episode. J. Aff. Disord. 83 (2004) 49-57
Thase M.E. Psychopharmacol. Bull. 36 Suppl 3 (2002) 12-25
Thase M.E., Sloan D.M., and Kornstein S.G. Remission as the critical outcome of depression treatment. Psychopharmacol. Bull. 36 suppl 3 (2002) 12-25
Tondo L., Burrai C., Scamonatti L., Weissenburger J., and Rush J. Comparison between clinician-rated and self-reported depressive symptoms in Italian psychiatric patients. Neuropsychobiology 19 (1988) 1-5
Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M., and Star*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163 (2006) 28-40
Ueki H., Holzapfel C., Washino K., Inoue M., Ogawa N., and Furukawa T. Concordance between self- and observer-ratings on Kasahara's inventory for the melancholic type personality. Psychiatry Clin. Neurosci. 56 (2002) 569-574
White J., White K., and Razani J. Effects of endogenicity and severity on consistency of standard depression rating scales. J. Clin. Psychiatry 45 (1984) 260-261
World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. Geneva, Switzerland: World Health Organization, 2001
Zimmerman M., Posternak M.A., and Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J. Psychiatr. Res. 38 (2004) 577-582
Zimmerman M., Posternak M.A., and Chelminski I. Using a self-report depression scale to identify remission in depressed outpatients. Am. J. Psychiatry 161 (2004) 1911-1913
Zimmerman M., Posternak M.A., and Chelminski I. Is the cutoff to define remission on the Hamilton rating scale for depression too high?. J. Of Nerv. Ment. Dis. 193 (2005) 170-175
Zimmerman M., McGlinchey J.B., Posternak M.A., Friedman M., Attiullah N., and Boerescu D. How should remission from depression be defined? The depressed patient's perspective. Am. J. Psychiatry 163 (2006) 148-150
Zlotnick C., Shea M.T., Pilkonis P.A., and Ryan C. Gender, type of treatment, dysfunctional attitudes, social support, life events, and depressive symptoms over naturalistic follow-up. Am. J. Psychiatry 153 8 (1996) 1021-1027